Clinical Development of a Novel Monoclonal Antibody Targeting Pancreatic and Colorectal Cancer

Philip M. Arlen
President and CEO
Precision Biologics

Presented by GTC, a conference production company • (626) 256-6405 • www.gtcbio.com
Clinical Development of a Novel Monoclonal Antibody Targeting Pancreatic and Colorectal Cancer

Philip M. Arlen, MD
President & CEO, Precision Biologics Inc
July 2014
Clinical Stage Biotechnology Company

Pipeline: 3 Tumor Specific Monoclonal antibodies

Therapeutics
Pancreatic & Colorectal Cancer

Diagnostics
- Patient clinical trials
- Early Detection Studies

Companion Diagnostics
Discovery platform is based on 20+ years of research and clinical testing pioneered by Dr. Ariel Hollinshead and colleagues.

Hollinshead’s patented vaccine strategy used pooled tumor tissues and membrane-associated proteins were extracted and fractionated for testing in humans by DTH.

The Hollinshead tumor vaccines were shown to be tumor-specific, that is, DTH responses were NOT observed in normal volunteers or in cancer patients with other cancer types.

In the 1970’s and early 1980’s, Hollinshead’s cancer vaccines were tested in Phase I, II, and III clinical trials in the United States. Published data demonstrated safety, combined with statistically significant anti-tumor responses and prolonged patient survival.
Phase-I Study of Colon Cancer Vaccine


- 22 patients with Dukes stage B2 through D Colon Cancer underwent surgical resection prior to TAA vaccine injection

- No systemic toxicity (hepatic, renal, GI, respiratory, or neurologic) was observed with the vaccine

- Results: **82% survival, 59% disease-free** (median follow-up 21 months)
Colon Cancer Vaccine Clinical Trial

Tumor Invasion in groin

Anti-tumor response & Regression 7 years post-treatment

Cell-mediated and humoral responses observed in 4th month
Neogenix sources of antigens/mAbs
ATTENTION!

The entire presentation will be provided to registered attendees only at the conference!

To view the rest of this exciting presentation and many more please register for the conference at

www.gtcbio.com